Resmetirom is a selective thyroid hormone receptor-beta (THR-β) agonist indicated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis… Read more













































Resmetirom is a selective thyroid hormone receptor-beta (THR-β) agonist indicated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), in adults with moderate to advanced liver fibrosis. This category provides comprehensive reference standards, including the active pharmaceutical ingredient, related impurities, metabolites, and stable isotope labelled compounds essential for rigorous pharmaceutical analysis. Laboratories utilize these high-quality materials for impurity profiling, method validation, and routine quality control to ensure regulatory compliance and therapeutic consistency. Stable isotope labelled versions of Resmetirom serve as reliable internal standards in mass spectrometry, facilitating accurate quantification in complex biological matrices during pharmacokinetic and metabolic studies. By providing access to structurally characterized pharmacopeial and non-pharmacopeial impurities, these standards support the development of robust analytical methods and the evaluation of drug stability throughout the product lifecycle, adhering to established international guidelines.